Portfolio of Gene Editing (CRISPR) Stocks

Here are 4 gene editing stocks that use CRISPR technology.


4 Portfolio of Gene Editing (CRISPR) Stocks

Name
& Monthly Returns

Symbol
& Snapshot

Recent Prices
& Trendline

Crispr TherapeuticsCRSP
Editas MedicineEDIT
Intellia TherapeuticsNTLA
Vertex PharmaceuticalsVRTX
Sparkline weekly price charts based on Alpha Vantage data.


Portfolio Values

To inspect the performance of the Portfolio of Gene Editing (CRISPR) Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.

All 4 stocks are included in the portfolio computations. The current value of the portfolio assumes that $2,500.00 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.

The current value of the $10,000 investment is $19,046. The percent return is 90.46%. The annualized return is 13.75%.



Portfolio Value Chart for Last 100 Daily Closes



Related Portfolios

Portfolio of Biotech Stocks

Portfolio of Genetic Testing Stocks

Portfolio of Genomics Stocks

Portfolio of Stem Cell Stocks